BACKGROUND: Many sepsis survivors develop chronic critical illness (CCI) and are assumed to be immunosuppressed, but there is limited clinical evidence to support this. We sought to determine whether the incidence of secondary infections and immunosuppressive biomarker profiles of patients with CCI differ from those with rapid recovery (RAP) after sepsis. METHODS: This prospective observational study evaluated 88 critically ill patients with sepsis and 20 healthy controls. Cohorts were defined based on clinical trajectory (early death, RAP, or CCI), whereas immunosuppression was clinically determined by the presence of a postsepsis secondary infection. Serial blood samples were collected for absolute lymphocyte counts (ALCs), monocytic human leukocyte antigen-DR (mHLA-DR) expression, and plasma-soluble programmed death-ligand 1 (sPD-L1) concentrations. RESULTS: Of the 88 patients with sepsis, 3 (3%) died within 14 days of sepsis onset, 50 (57%) experienced RAP, and 35 (40%) developed CCI. Compared with RAP patients, CCI patients exhibited a higher incidence and overall number of infections adjusted for hospital length of stay. ALC and mHLA-DR levels were dramatically reduced at the time of sepsis diagnosis when compared with healthy controls, whereas sPD-L1 concentrations were significantly elevated. There were no differences between RAP and CCI patients in ALC, sPD-L1, or mHLA-DR at the time of diagnosis or within 24 h after sepsis diagnosis. However, in contrast to the RAP group, CCI patients failed to exhibit any trend toward restoration of normal values of ALC, HLA-DR, and sPD-L1. CONCLUSIONS: Septic patients demonstrate clinical and biological evidence to suggest they are immunosuppressed at the time of sepsis diagnosis. Those who develop CCI have a greater incidence of secondary infections and persistently aberrant markers of impaired host immunity, although measurements at the time of sepsis onset did not distinguish between subjects with RAP and CCI.
BACKGROUND: Many sepsis survivors develop chronic critical illness (CCI) and are assumed to be immunosuppressed, but there is limited clinical evidence to support this. We sought to determine whether the incidence of secondary infections and immunosuppressive biomarker profiles of patients with CCI differ from those with rapid recovery (RAP) after sepsis. METHODS: This prospective observational study evaluated 88 critically ill patients with sepsis and 20 healthy controls. Cohorts were defined based on clinical trajectory (early death, RAP, or CCI), whereas immunosuppression was clinically determined by the presence of a postsepsis secondary infection. Serial blood samples were collected for absolute lymphocyte counts (ALCs), monocytic human leukocyte antigen-DR (mHLA-DR) expression, and plasma-soluble programmed death-ligand 1 (sPD-L1) concentrations. RESULTS: Of the 88 patients with sepsis, 3 (3%) died within 14 days of sepsis onset, 50 (57%) experienced RAP, and 35 (40%) developed CCI. Compared with RAPpatients, CCIpatients exhibited a higher incidence and overall number of infections adjusted for hospital length of stay. ALC and mHLA-DR levels were dramatically reduced at the time of sepsis diagnosis when compared with healthy controls, whereas sPD-L1 concentrations were significantly elevated. There were no differences between RAP and CCIpatients in ALC, sPD-L1, or mHLA-DR at the time of diagnosis or within 24 h after sepsis diagnosis. However, in contrast to the RAP group, CCIpatients failed to exhibit any trend toward restoration of normal values of ALC, HLA-DR, and sPD-L1. CONCLUSIONS: Septic patients demonstrate clinical and biological evidence to suggest they are immunosuppressed at the time of sepsis diagnosis. Those who develop CCI have a greater incidence of secondary infections and persistently aberrant markers of impaired host immunity, although measurements at the time of sepsis onset did not distinguish between subjects with RAP and CCI.
Authors: Juan C Mira; Lori F Gentile; Brittany J Mathias; Philip A Efron; Scott C Brakenridge; Alicia M Mohr; Frederick A Moore; Lyle L Moldawer Journal: Crit Care Med Date: 2017-02 Impact factor: 7.598
Authors: David S Y Ong; Marc J M Bonten; Cristian Spitoni; Frans M Verduyn Lunel; Jos F Frencken; Janneke Horn; Marcus J Schultz; Tom van der Poll; Peter M C Klein Klouwenberg; Olaf L Cremer Journal: Clin Infect Dis Date: 2017-05-01 Impact factor: 9.079
Authors: Xavier Frigola; Brant A Inman; Christine M Lohse; Christopher J Krco; John C Cheville; R Houston Thompson; Bradley Leibovich; Michael L Blute; Haidong Dong; Eugene D Kwon Journal: Clin Cancer Res Date: 2011-02-25 Impact factor: 12.531
Authors: Mitchell M Levy; Mitchell P Fink; John C Marshall; Edward Abraham; Derek Angus; Deborah Cook; Jonathan Cohen; Steven M Opal; Jean-Louis Vincent; Graham Ramsay Journal: Crit Care Med Date: 2003-04 Impact factor: 7.598
Authors: H D Volk; P Reinke; D Krausch; H Zuckermann; K Asadullah; J M Müller; W D Döcke; W J Kox Journal: Intensive Care Med Date: 1996-10 Impact factor: 17.440
Authors: Lori F Gentile; Alex G Cuenca; Philip A Efron; Darwin Ang; Azra Bihorac; Bruce A McKinley; Lyle L Moldawer; Frederick A Moore Journal: J Trauma Acute Care Surg Date: 2012-06 Impact factor: 3.313
Authors: M Ditschkowski; E Kreuzfelder; V Rebmann; S Ferencik; M Majetschak; E N Schmid; U Obertacke; H Hirche; U F Schade; H Grosse-Wilde Journal: Ann Surg Date: 1999-02 Impact factor: 12.969
Authors: Erin L Vanzant; Cecilia M Lopez; Tezcan Ozrazgat-Baslanti; Ricardo Ungaro; Ruth Davis; Alex G Cuenca; Lori F Gentile; Dina C Nacionales; Angela L Cuenca; Azra Bihorac; Christiaan Leeuwenburgh; Jennifer Lanz; Henry V Baker; Bruce McKinley; Lyle L Moldawer; Frederick A Moore; Philip A Efron Journal: J Trauma Acute Care Surg Date: 2014-01 Impact factor: 3.313
Authors: Richard S Hotchkiss; Elizabeth Colston; Sachin Yende; Derek C Angus; Lyle L Moldawer; Elliott D Crouser; Greg S Martin; Craig M Coopersmith; Scott Brakenridge; Florian B Mayr; Pauline K Park; June Ye; Ian M Catlett; Ihab G Girgis; Dennis M Grasela Journal: Crit Care Med Date: 2019-05 Impact factor: 7.598
Authors: Anis Davoudi; Duane B Corbett; Tezcan Ozrazgat-Baslanti; Azra Bihorac; Scott C Brakenridge; Todd M Manini; Parisa Rashidi Journal: IEEE EMBS Int Conf Biomed Health Inform Date: 2018-04-09
Authors: Scott C Brakenridge; Philip A Efron; Michael C Cox; Julie A Stortz; Russell B Hawkins; Gabriela Ghita; Anna Gardner; Alicia M Mohr; Stephen D Anton; Lyle L Moldawer; Frederick A Moore Journal: Ann Surg Date: 2019-09 Impact factor: 12.969
Authors: Philip A Efron; Alicia M Mohr; Azra Bihorac; Hiroyuki Horiguchi; McKenzie K Hollen; Mark S Segal; Henry V Baker; Christiaan Leeuwenburgh; Lyle L Moldawer; Frederick A Moore; Scott C Brakenridge Journal: Surgery Date: 2018-05-26 Impact factor: 3.982
Authors: Martin D Rosenthal; Jayshil Patel; Kyle Staton; Robert G Martindale; Frederick A Moore; Gilbert R Upchurch Journal: Curr Gastroenterol Rep Date: 2018-08-04
Authors: Scott C Brakenridge; Philip A Efron; Julie A Stortz; Teczan Ozrazgat-Baslanti; Gabriela Ghita; Zhongkai Wang; Azra Bihorac; Alicia M Mohr; Babette A Brumback; Lyle L Moldawer; Frederick A Moore Journal: J Trauma Acute Care Surg Date: 2018-08 Impact factor: 3.313
Authors: Julie A Stortz; McKenzie K Hollen; Dina C Nacionales; Hiroyuki Horiguchi; Ricardo Ungaro; Marvin L Dirain; Zhongkai Wang; Quran Wu; Kevin K Wu; Ashok Kumar; Thomas C Foster; Brian D Stewart; Julia A Ross; Marc Segal; Azra Bihorac; Scott Brakenridge; Frederick A Moore; Stephanie E Wohlgemuth; Christiaan Leeuwenburgh; Alicia M Mohr; Lyle L Moldawer; Philip A Efron Journal: Crit Care Med Date: 2019-11 Impact factor: 7.598